COMPASS Pathways (NASDAQ:CMPS) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note released on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $11.00 price objective on the stock.

Several other equities research analysts have also recently issued reports on the stock. Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. HC Wainwright decreased their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $27.33.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS opened at $3.92 on Thursday. The company has a 50-day simple moving average of $4.06 and a 200-day simple moving average of $5.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The company has a market cap of $268.21 million, a PE ratio of -1.78 and a beta of 2.28.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tang Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at approximately $3,780,000. RTW Investments LP purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at approximately $11,714,000. Point72 Asset Management L.P. raised its stake in shares of COMPASS Pathways by 15.4% during the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company’s stock valued at $257,000 after purchasing an additional 9,099 shares during the period. Integral Health Asset Management LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at approximately $756,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of COMPASS Pathways by 205.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company’s stock valued at $479,000 after purchasing an additional 85,213 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.